Epstein-Barr virus-targeted therapy for AIDS-related primary lymphoma of the central nervous system

Karen S. Slobod, Gregory H. Taylor, John T. Sandlund, Priscilla Furth, Kathleen J. Helton, John W. Sixbey

Research output: Contribution to journalArticlepeer-review

Abstract

Epstein-Barr virus (EBV) targeted therapeutic strategies for viral associated malignant diseases have received only perfunctory consideration, first, because latent herpesviruses have been intractable to antiviral chemotherapy and, second, because the role EBV has in maintenance of the malignant cell phenotype has been uncertain. Two patients with EBV related primary central nervous system lymphoma (PCNSL) in the setting of advanced AIDS, were treated with low dose hydroxyurea based on in vitro anti-EBV activity. The responses obtained here suggest the promise of antiviral approaches in select cancers.

Original languageEnglish (US)
Pages (from-to)1493-1494
Number of pages2
JournalLancet
Volume356
Issue number9240
DOIs
StatePublished - Oct 28 2000

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Epstein-Barr virus-targeted therapy for AIDS-related primary lymphoma of the central nervous system'. Together they form a unique fingerprint.

Cite this